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Background: The benefits of endovascular repair of ruptured abdominal aortic aneurysm remain
controversial, without any strong evidence about advantages in specific subgroups.
Methods: An individual-patient data meta-analysis of three recent randomized trials of endovascular
versus open repair of abdominal aortic aneurysm was conducted according to a prespecified analysis plan,
reporting on results to 90 days after the index event.
Results: The trials included a total of 836 patients. The mortality rate across the three trials was 31⋅3
per cent for patients randomized to endovascular repair/strategy and 34⋅0 per cent for those randomized
to open repair at 30 days (pooled odds ratio 0⋅88, 95 per cent c.i. 0⋅66 to 1⋅18), and 34⋅3 and 38⋅0 per
cent respectively at 90 days (pooled odds ratio 0⋅85, 0⋅64 to 1⋅13). There was no evidence of significant
heterogeneity in the odds ratios between trials. Mean(s.d.) aneurysm diameter was 8⋅2(1⋅9) cm and the
overall in-hospital mortality rate was 34⋅8 per cent. There was no significant effect modification with age
or Hardman index, but there was indication of an early benefit from an endovascular strategy for women.
Discharge from the primary hospital was faster after endovascular repair (hazard ratio 1⋅24, 95 per cent
c.i. 1⋅04 to 1⋅47). For open repair, 30-day mortality diminished with increasing aneurysm neck length
(adjusted odds ratio 0⋅69 (95 per cent c.i. 0⋅53 to 0⋅89) per 15mm), but aortic diameter was not associated
with mortality for either type of repair.
Conclusion: Survival to 90 days following an endovascular or open repair strategy is similar for all patients
and for the restricted population anatomically suitable for endovascular repair. Women may benefit more
from an endovascular strategy thanmen and patients are, on average, discharged sooner after endovascular
repair.
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Introduction
There have been four randomized trials of endovascular
versus open repair of ruptured abdominal aortic aneurysm
(AAA), all with the intention of showing the superiority
of endovascular aneurysm repair (EVAR). The first trial
was a single-centre pilot trial of 32 patients conducted in
Nottingham, UK, between 2002 and 2004; the 30-day
mortality rate was 53 per cent in each treatment group1.
Following this, two further trials of similar design were
developed in the Amsterdam area of the Netherlands
(Amsterdam Acute Aneurysm, AJAX trial) and in France
(Endovasculaire versus Chirurgie dans les Anévrysmes
Rompus, ECAR trial); patients were considered for ran-
domization only if their aortic anatomy was suitable for
EVAR. The sample sizes of these trials were informed by
systematic reviews2,3 of observational series that showed a
strong benefit in operative mortality for EVAR compared
with open repair. The Amsterdam trial4 randomized 116
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patients and failed to show any benefit for EVAR with
respect to either the primary endpoint (combined 30-day
morbidity and mortality) or 30-day mortality. The French
trial5 randomized 107 patients and again failed to show
any significant difference in 30-day mortality between
the randomized groups. The last trial to start (Immediate
Management of the Patient with Ruptured Aneurysm:
Open Versus Endovascular repair, IMPROVE trial), and
the largest, was in the UK (with 1 Canadian centre),
but was based on a different design, with patients being
randomized at the point of clinical diagnosis of ruptured
aneurysm to an endovascular strategy (EVAR if found
anatomically suitable on subsequent CT, open repair if
not) versus open repair; this trial was designed to have more
than 90 per cent power to detect a 14 per cent difference
in 30-day mortality with recruitment of 600 patients. Even
with 613 patients, IMPROVE6 failed to show a 30-day
mortality benefit for the endovascular strategy, partly
owing to a lower mortality rate than anticipated in the
open repair group. It was large enough to allow limited
subgroup analysis6. An editorial commentary7 accompany-
ing publication of this trial suggested that the sample size
calculations might have been too optimistic and that, given
the advances in intensive therapy, 90-day survival should
have been chosen as the primary outcome. For patients,
and their families, the most important outcome is reaching
home alive, not 30-day mortality.
To counter some of these criticisms and permit more
robust subgroup analyses, the ruptured aneurysm trial-
ists agreed to collaborate to allow an individual-patient
meta-analysis of outcomes to 90 days after rupture. Given
the different trial designs, an individual-patient approach
has the added advantage of pooling data from similar
groups of patients, for example by selecting out those
anatomically suitable for EVAR from the IMPROVE
trial for comparison with patients from the AJAX and
ECAR trials.
Unfortunately, the data from the Nottingham trial could
not be retrieved, so this meta-analysis is based on the
data from the AJAX4, ECAR5 and IMPROVE6 trials only.
The purpose was to test the hypotheses that, particularly
for patients anatomically suitable for EVAR, endovascular
repair offers an improvement in 90-day survival and earlier
hospital discharge compared with open repair, as well as
identifying whether specific subgroup analyses by age, sex
and Hardman index (a validated morbidity score for rup-
tured aneurysm8,9) had better 90-day survival with EVAR.
In addition, the meta-analysis presents 30-day outcomes,
including whether morphological features affected 30-day
mortality and whether abdominal compartment syndrome
was more common after EVAR than open repair.
Methods
The methods for the three trials included in this
meta-analysis have been published previously10–12. The
AJAX trial randomized 116 patients, with CT showing
probable rupture, and patients being eligible for both open
and endovascular repair, in three centres between 2004
and 2011; sealed envelopes were used for randomization
to either open or endovascular repair (aortouni-iliac grafts
for EVAR). The ECAR trial randomized 107 patients, with
CT showing confirmed rupture and an aortic anatomy
suitable for EVAR, and a systolic BP exceeding 80mmHg;
treatment allocation was by weekly rotation, in 14 centres
between 2008 and 2012. The IMPROVE trial randomized
613 eligible patients with an in-hospital clinical diagnosis
of ruptured aneurysm in 29 centres between 2009 and
2013; an independent contractor provided telephone
randomization, with computer-generated assignation of
patients in a 1 : 1 ratio, using variable block size and strati-
fied by centre. For IMPROVE, patients were randomized
before CT to either an endovascular strategy (with open
repair if EVAR was not anatomically feasible) or open
repair.
The three data sets were merged based on fields available
in the case record forms of the largest trial (IMPROVE),
range checks were conducted and queries resolved with the
individual trial coordinating centres.
Statistical analysis
The primary analyses considered the groups as randomized
within each trial, irrespective of the different trial designs.
Mortality was assessed at both 30 and 90 days after ran-
domization (for IMPROVE) and following admission (for
AJAX and ECAR), with 90-day survival being the primary
outcome of interest. The odds ratio for both 30- and 90-day
mortality for the endovascular strategy or EVAR versus
open repair was estimated using logistic regression, adjust-
ing for trial to obtain a one-stage fixed-effect pooled esti-
mate. A secondary analysis was conducted by estimating the
odds ratio separately within each study and then pooling
using random-effects meta-analysis, with between-study
heterogeneity estimated using a method of moments13.
The proportion of between-trial variability beyond that
expected by chance was quantified using the I2 statistic14.
Analyses were then repeated for odds ratios estimated from
logistic regression models adjusted for age, sex and Hard-
man index. Multiple imputation using chained equations
was used to account for missing baseline co-variables in
adjusted analyses (Appendix S1, supporting information)15.
Secondary analyses were conducted with the pur-
pose of making the groups in the different trials more
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homogeneous. Only those patients with a final diagno-
sis of ruptured AAA and considered suitable for EVAR
were retained in the analyses. For AJAX and ECAR,
suitability for EVAR was a prerequisite for inclusion in
the trial. For the IMPROVE trial, suitability for EVAR
was defined as either local CT assessment of suitability
or, if not assessed locally, a ‘within liberal instructions
for use’ definition from a core laboratory CT analysis
was used.
Kaplan–Meier survival plots and cumulative incidence
of time to primary hospital discharge were produced by
randomized group within each trial separately and accom-
panied by a log rank test. A Cox proportional hazards
model was used to assess whether the randomized groups
differed in terms of the cause-specific hazard of primary
hospital discharge (competing in-hospital mortality not
withstanding).
The subgroups age, sex and Hardman index were
assessed for differences in the effect of the endovascu-
lar and open strategies by including an interaction term
between the subgroup and randomized group in a logistic
regression model.
The reporting of complications and reinterventions was
very different in the three trials, but they all reported on the
use of occlusion balloons and the incidence of abdominal
compartment syndrome and other non-occlusive mesen-
teric hypoperfusion syndromes16; however, the abdomi-
nal compartment syndrome data for the AJAX trial were
collected retrospectively.
The effect of aortic morphology on 30-day mortality was
also assessed within each trial for AAA diameter, aortic
neck diameter, aortic neck length and proximal neck α
angulation. Because these analyses are not a comparison
between randomized groups, all analyses were adjusted
for the following potential confounding factors: age, sex
(AJAX and IMPROVE), Hardman index, admission mean
arterial BP, treatment commenced and randomized group
(IMPROVE only). Analysis of each morphological variable
was conducted both adjusted and unadjusted for the other
three morphological variables.
Table 1 Descriptive statistics for the three trials
AJAX
(n=116)
ECAR
(n=107)
IMPROVE
(n=613)
Randomized group
EVAR/EVAR strategy 57 (49⋅1) 56 (52⋅3) 316 (51⋅5)
Open repair 59 (50⋅9) 51 (47⋅7) 297 (48⋅5)
rAAA suitable for EVAR‡ n=113 n=104 n=310
EVAR/EVAR strategy 57 (50⋅4) 54 (51⋅9) 168 (54⋅2)
Open repair 56 (49⋅6) 50 (48⋅1) 142 (45⋅8)
Procedure commenced
EVAR 57 (49⋅1) 56 (52⋅3) 192 (31⋅3)
Open repair 59 (50⋅9) 50 (46⋅7) 331 (54⋅0)
No aneurysm repair 0 (0) 1 (0⋅9) 90 (14⋅7)
Age (years)* 74⋅2(9⋅4) 74⋅4(10⋅6) 76⋅7(7⋅6)
Sex ratio (M : F) 99 : 17 97 : 10 480 : 133
Admission mean arterial BP (mmHg)*§ n=113 n=104 n=601
87(27) 108(30) 81(24)
Hardman index n=61 n=105 n=539
0 26 (43) 41 (39⋅0) 164 (30⋅4)
1 19 (31) 44 (41⋅9) 254 (47⋅1)
2 12 (20) 11 (10⋅5) 94 (17⋅4)
≥3 4 (7) 9 (8⋅6) 27 (5⋅0)
Morphology
Maximum aortic diameter (mm)* n=92
76(16)
n=106
77(20)
n=518
84(19)
Aneurysm neck diameter (mm)*¶ n=92
26(4)
n=106
24(4)
n=430
26(4)
Neck length (mm)† n=92
25 (19–34)
n=101
21 (15–30)
n=481
22 (10–34)
Proximal neck angle (∘)* n=92
39(21)
n=96
34(26)
n=478
33(20)
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) and †median (i.q.r.). ‡Suitability for endovascular aneurysm repair
(EVAR) in IMPROVE defined by local assessment of suitability if available; otherwise a core laboratory assessment of ‘within liberal instructions for use’
was used to define suitability. Suitability not assessed in 46 ruptured abdominal aortic aneurysms (rAAAs) in IMPROVE and one in ECAR. §Mean arterial
BP recorded only in ECAR; for AJAX and IMPROVE it was approximated by 2/3 diastolic+ 1/3 systolic BP. ¶IMPROVE and ECAR measured top neck
diameter; AJAX measured maximum neck diameter.
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Table 2 Operative data and outcomes
AJAX (n=116) ECAR (n=107) IMPROVE (n= 613)
Time to start of repair (h)*†
Randomized to EVAR 1⋅23 2⋅9 0⋅77
Randomized to open repair 0⋅75 1⋅3 0⋅61
Operative data
Anaesthesia initiated in those who n=55 n=56 n=188
commenced EVAR
General anaesthetic 29 (53) 48 (86) 85 (45⋅2)
Local anaesthetic 26 (47) 8 (14) 103 (54⋅8)
Graft type
EVAR commenced n=57 n=56 n=182
Aortouni-iliac 49 (86) 43 (77) 39 (21⋅4)
Bifurcated 4 (7) 12 (21) 136 (74⋅7)
Tube/other‡ 4 (7) 1 (2) 7 (3⋅8)
Open repair commenced n=57 n=48 n=293
Aortouni-iliac 0 (0) 0 (0) 1 (0⋅3)
Bifurcated 7 (12) 22 (46) 55 (18⋅8)
Tube 50 (88) 26 (54) 237 (80⋅9)
Length of time in theatre for those who n=111 n=100 n=501
commenced EVAR or open repair (min)* 177 (150–210) 180 (135–250) 180 (147–235)
Time of surgery for those who commenced
EVAR or open repair
In routine working hours§ 42 of 116 (36⋅2) 28 of 105 (26⋅7) 173 of 515 (33⋅6)
Monday–Friday 96 of 116 (82⋅8) 81 of 106 (76⋅4) 404 of 515 (78⋅5)
Outcomes
Discharged alive 84 of 116 (72⋅4) 75 of 104 (72⋅1) 384 of 613 (62⋅6)
Death within 30 days
EVAR 12 of 57 (21) 10 of 55 (18) 112 of 316 (35⋅4)
Open repair 15 of 59 (25) 12 of 50 (24) 111 of 297 (37⋅4)
Missing 0 2 0
Death within 90 days
EVAR 15 of 57 (26) 11 of 53 (21) 120 of 316 (38⋅0)
Open repair 17 of 59 (29) 17 of 45 (38) 118 of 296 (39⋅9)
Missing 0 9 1
Place of discharge n=84 n=65 n=384
Another hospital 2 (2) 3 (5) 36 (9⋅4)
Home 64 (76) 38 (58) 330 (85⋅9)
Nursing, residential or sheltered home 18 (21) 23 (35) 8 (2⋅1)
Other 0 (0) 1 (2) 10 (2⋅6)
Length of stay for those discharged n=84 n=75 n=384
alive (days)* 14 (8–22) 15 (11– 26) 11 (7–20)
Values in parentheses are percentages unless otherwise indicated; *values are median (i.q.r.). †From admission in AJAX and ECAR, and from
randomization in IMPROVE. ‡Includes conversion to open repair and extra-anatomic bypass. §Monday to Friday between 08.30 and 16.30 hours in the
UK; Monday to Friday between 08.00 and 17.00 hours in the Netherlands and France. EVAR, endovascular aneurysm repair.
Results
The baseline characteristics of the 836 patients are shown
in Table 1. Because the design of the IMPROVE trial was
different from that of the other two trials, the number of
patients with ruptured aortoiliac aneurysm (core labora-
tory diagnosis) who were anatomically suitable for EVAR is
shown. The one patient in ECAR who did not have direct
aneurysm repair underwent axillobifemoral bypass. The
demographic details are shown for all 836 patients random-
ized. The patients in IMPROVE tended to be older, with
more women included, and patients had larger aneurysms.
The operative details and discharge data for the patients
are shown in Table 2. Both AJAX and ECAR used predom-
inantly aortouni-iliac endografts, which restricted com-
pletion of the procedure, with femorofemoral cross-over
grafts, under local anaesthesia. The in-hospital mortality
rate was higher for IMPROVE (37⋅4 per cent) than for
either AJAX (27⋅6 per cent) or ECAR (27⋅9 per cent) but,
for those discharged alive, patients in IMPROVE were dis-
charged sooner and more often directly to home. Overall
survival to 90 days is shown in Fig. 1.
At 90 days there was slight evidence of heterogeneity in
the odds ratios (I2=18⋅9 per cent), with the odds ratio
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Fig. 1 Kaplan–Meier survival plots up to 90 days by trial and randomized group: a AJAX, b ECAR, c IMPROVE and d patients with
ruptured abdominal aortic aneurysm (rAAA) suitable for endovascular repair (EVAR) in IMPROVE. a P = 0⋅866, b P = 0⋅048,
c P= 0⋅899, d P = 0⋅890 (log rank test)
in ECAR being lower than in the other trials, although
several patients in this trial had been lost to follow-up
(Fig. 2a). Despite this, the overall pooled odds ratio for
survival at 90 days was not significant (0⋅85, 95 per cent
c.i. 0⋅64 to 1⋅13), with a random-effects estimate of 0⋅82
(0⋅56 to 1⋅18). Adjusted analyses gave similar results and
those that restricted the population to ruptured aneurysms
suitable for EVAR were more homogeneous (pooled odds
ratio 0⋅74, 0⋅51 to 1⋅08) (Fig. 2b).
Similar results were seen at 30 days, with little evidence
of a benefit of an endovascular strategy or EVAR among
any of the three trials comparing patients as randomized
(Fig. S1a, supporting information), and estimated only in
patients with confirmed rupture and aortic anatomy suit-
able for EVAR (Fig. S1b, supporting information).
There was also little evidence of the treatment effect
changing by age or Hardman index at either 30 days
(Fig. S2, supporting information) or 90 days (Fig. 3). How-
ever, for age, 90-day results were heterogeneous across the
trials (I2 = 74⋅2 per cent, P= 0⋅021), with AJAX suggesting
a benefit of open repair and ECAR suggesting a benefit
of EVAR for older patients. There were no early deaths
among women in the ECAR trial. In the pooled analysis,
women benefited more from an endovascular strategy than
men (ratio of odds ratios 0⋅49, 95 per cent c.i. 0⋅24 to 0⋅99).
A similar ratio of odds ratios was estimated at 30 days (0⋅47,
0⋅23 to 0⋅97).
Although the IMPROVE trial had suggested that the
30-day mortality for open repair was higher when patients
were randomized outside routine working hours, this find-
ing could not be substantiated across the three trials.
Occlusion balloons were not used widely, but were
employed more often in ECAR (18 of 107, 16⋅8 per cent),
than in either AJAX (4 of 116, 3⋅4 per cent) or IMPROVE
(32 of 522, 6⋅1 per cent). The reporting of complications
was very different in the three trials; however, abdominal
hypoperfusion syndromes (including abdominal compart-
ment syndrome) were reported in all trials (Table 3). Only
ECAR routinely reported abdominal compartment syn-
drome according to established methods17 and searched
actively for colonic ischaemia, perhaps explaining the
higher rates reported in this trial. Abdominal compart-
ment syndrome was reported more often in the EVAR
groups of AJAX and ECAR, but not in the endovascular
strategy group of IMPROVE (pooled odds ratio 1⋅64, 95
per cent c.i. 0⋅87 to 3⋅09). However, in all trials there was
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Overall (I2 = 18·6%, P = 0·293)
Trial
ECAR
AJAX
IMPROVE
0·85 (0·64, 1·13)
0·43 (0·18, 1·06)
0·88 (0·39, 1·99)
0·92 (0·67, 1·28)
Odds ratioOdds ratio
100·00
Weight (%) No. of
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Odds ratioOdds ratio Weight (%) No. of
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98
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IMPROVE
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a  All patients
b  Patients with rAAA eligible for EVAR
Fig. 2 Analysis of 90-day mortality by randomized group: a all patients and b patients with ruptured abdominal aortic aneurysm (rAAA)
eligible for both endovascular aneurysm repair (EVAR) and open repair. Odds ratios are shown with 95 per cent c.i.
Trial Ratio of odds ratios Ratio of odds ratios
No. of
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1161·73 (0·98, 3·05)
0·60 (0·37, 0·98)
0·88 (0·70, 1·11)
0·91 (0·75, 1·10)
1·44 (0·16, 12·79)
0·17 (0·0052, 5·76)
0·42 (0·19, 0·92)
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Fig. 3 Analysis of 90-day mortality by randomized group with subgroup analyses for age, sex and Hardman index. Multiple imputation
was used for Hardman index. With small numbers in the ECAR trial (2 of 9 deaths within 90 days in women), the trial-specific
subgroup effect for sex was calculated by adding a continuity correction of 0⋅5 to all cells in the contingency table. Ratios of odds ratios
are shown with 95 per cent c.i. EVAR, endovascular aneurysm repair
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Table 3 Reported incidence of abdominal compartment
syndrome and other mesenteric hypoperfusion syndromes,
colonic ischaemia and mesenteric ischaemia16 by randomized
group
Trial Syndrome
EVAR/endovascular
strategy Open repair
AJAX ACS
CMI
5 of 57 (9)
2 of 57 (4)
2 of 59 (3)
5 of 59 (8)
ECAR ACS
CMI
8 of 56 (14)
4 of 56 (7)
1 of 51 (2)
8 of 51 (16)
IMPROVE* ACS
CMI
14 of 259 (5⋅4)
14 of 259 (5⋅4)
13 of 243 (5⋅3)
19 of 243 (7⋅8)
Values in parentheses are percentages. *The denominator is the number
of ruptured aneurysms repaired. EVAR, endovascular aneurysm repair;
ACS, abdominal compartment syndrome; CMI, chronic mesenteric
ischaemia.
an indication of a lower incidence of isolated mesen-
teric and/or colonic ischaemia in the endovascular
strategy or EVAR groups; the pooled odds ratio (0⋅57,
0⋅32 to 1⋅01) narrowly failed to achieve statistical
significance.
There was wide variation in discharge policy across
the three trials, with many patients in ECAR being dis-
charged to other care facilities, whereas more patients in
IMPROVE were discharged directly to home. Overall,
for patients discharged alive from the vascular surgical
centre, the duration of primary hospital stay was shorter
for patients in the endovascular strategy or EVAR groups
(pooled hazard ratio for discharge 1⋅24, 95 per cent c.i.
Overall  (I2 = 0·0%, P = 0·717)
Trial
IMPROVE
AJAX
ECAR
1·24 (1·04, 1·47)
Hazard ratioHazard ratio
1·28 (1·05, 1·57)
1·05 (0·68, 1·62)
1·23 (0·77, 1·97)
100·00
Weight (%)
71·40
15·56
13·04
No. of
patients
613
116
105
Favours open repair
0·6 0·8 1·0 1·5 2·0
Favours EVAR/EVAR strategy
Fig. 4 Hazard ratios, with 95 per cent c.i., for time to discharge alive from primary admission hospital by randomized group. EVAR,
endovascular aneurysm repair
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Fig. 5 Effect of aneurysm neck length on 30-day mortality, by treatment commenced. The analysis was restricted to patients with
ruptured abdominal aortic aneurysm who underwent CT, commenced treatment and did not have a common iliac aneurysm. All
analyses were adjusted for age, sex, Hardman index, admission mean arterial BP, treatment commenced and randomized group.
Multiple imputation was used to account for missing data. Odds ratios of 30-day mortality per 15-mm increase in aneurysm neck length
are shown with 95 per cent c.i. EVAR, endovascular aneurysm repair
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1⋅04 to 1⋅47) versus open repair (Fig. 4; Fig. S3, supporting
information).
The morphological parameters for aneurysms in the
three trials are shown in Table 1. Patients in IMPROVE
had larger aneurysm diameters and a very different dis-
tribution of aneurysm neck lengths compared with the
other trials (Fig. S4, supporting information). As previ-
ously observed for the IMPROVE trial18, aneurysm neck
length (Fig. 5), but not AAA diameter, neck diameter or
proximal neck angle (Figs. S5–S7, supporting information),
appeared to be a predictor of 30-day mortality, particularly
after open repair. For open repair, for each 15-mm increase
in neck length, 30-daymortality decreased (odds ratio 0⋅69,
95 per cent c.i. 0⋅53 to 0⋅89); with both operations com-
bined the association was slightly weaker (odds ratio 0⋅80,
0⋅66 to 0⋅97).
Discussion
The best evidence comes from synthesis of the results
of randomized trials. Three recent randomized trials of
endovascular versus open repair of ruptured AAA showed
no significant survival benefit at 90 days for endovascular
repair (pooled odds ratio 0⋅85, 95 per cent c.i. 0⋅64 to
1⋅13), but with slight heterogeneity. Perhaps the hetero-
geneity was expected given that the trials had very different
designs, although estimating the extent of between-study
heterogeneity is difficult with only three trials19. The
additional flexibility of individual-patient meta-analysis
also allowed only specific patient subsets to be included in
the meta-analysis. For instance, when the analysis included
only those patients in IMPROVE with confirmed rupture
eligible for both treatments, as in the AJAX and ECAR
trials, at 90 days the trial odds ratios were more homo-
geneous and the pooled odds ratio was lower, but with a
wider confidence interval (0⋅74, 95 per cent c.i. 0⋅51 to
1⋅08) because a smaller number of patients contributed to
this analysis. Similarly, at 30 days there was no evidence
that EVAR offered a survival advantage in patients with
confirmed rupture eligible for both endovascular and
open repair.
Another benefit of an individual-patient meta-analysis
is the ability to identify subgroups of patients who may
benefit from a specific treatment. Women appeared to be
under-represented in both the ECAR and AJAX trials,
so the estimate of the influence of sex was dominated by
the larger IMPROVE trial. Women appear to gain twice
as much benefit from an endovascular strategy or EVAR
versus open repair thanmen, although the pooled effect was
of borderline significance. The reasons for this potential
benefit in women are still uncertain, although morphology
may play a role18. This begins to suggest that, although
further research is needed, EVAR should be a more
common treatment option for women. The weak trend for
patients with higher Hardman index (more unfit) to have
better 30-day survival after EVAR was not substantiated
across the three trials and there was no clear effect of age.
The three trials were set in different healthcare systems,
as clearly shown by the time to discharge and destination
after discharge. Patients in France and the Netherlands
stayed in hospital longer andweremore often discharged to
a step-down care facility than patients in IMPROVE,where
more patients were discharged directly to home. Neverthe-
less the time to discharge was shorter in the endovascular
strategy or EVAR groups. In contrast, for each trial, it took
longer to get a patient to EVAR than to open repair, the
difference being greatest in France. This too is likely to be
a reflection of both the stability of the patient, with ECAR
having the most stable patients, and the different health-
care organizations. There is weak evidence that delays in
time to treatment influence survival adversely20,21. The
longer time taken to start definitive EVAR could have con-
tributed to some of the anticipated benefit of endovascular
repair on 30-day mortality being eroded.
The specificity of CT for the detection of ruptured AAA
has been questioned22. In the AJAX trial three patients
who underwent open repair were found to have an intact
AAA but a different pathology, such as bleeding liver
tumour or Crohn’s disease. At endovascular repair, the
underlying cause of admission might not have been ascer-
tained correctly in a few patients, potentially increasing
the mortality of those in the EVAR/endovascular strategy
groups.
The largest trial, IMPROVE, also conducted cohort
analyses and two of the observations reported were assessed
in individual patients from the three trials. The findings
from IMPROVE included the observation of higher mor-
tality risk for open repair outside routine working hours23
and the strong influence of aneurysm neck length on
mortality after open repair18. Overall there was no evi-
dence for a higher mortality rate among patients treated
outside routine working hours. The strong relationship
between short aneurysm neck length and high mortal-
ity after open repair may help explain why the mortality
rate after open repair remains high; around one-quarter
of the patients contributed by the IMPROVE trial had
a juxtarenal aneurysm (aneurysm neck length 0–9mm)
and were not eligible for conventional EVAR. Open juxta-
renal aneurysm repair requires cross-clamping of the aorta
above the renal arteries, with inevitable compromise of
the visceral circulation, especially in shocked patients. In
contrast, for longer aneurysm necks (15mm or more), an
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infrarenal aortic clamp is likely to be used for open repair,
with operative mortality similar to that for EVAR18. In the
future, the reporting of results for open repair of ruptured
AAA should be in two categories: infrarenal aneurysms and
juxtarenal aneurysms.
Some other clinical messages are consistent across all
three trials. The reported rate of abdominal compartment
syndrome was low, similar to the 8 per cent reported in a
recent meta-analysis24, and only the ECAR trial suggested
a higher rate after EVAR. Abdominal compartment syn-
drome is characterized by intra-abdominal hypertension.
As bladder pressures were measured only in the ECAR
trial, underdetection of abdominal compartment syndrome
is likely. However, other non-occlusive mesenteric hypo-
perfusion syndromes are recognized, including mesenteric
and colonic ischaemia, and these tended to be more com-
mon after open repair16. The total rate of non-occlusive
hypoperfusion complications reported was much higher
than the 8 per cent noted for abdominal compartment
syndrome.
This individual-patient meta-analysis across three Euro-
pean trials concluded that there is no early survival benefit
for an endovascular strategy or EVAR following ruptured
AAA, although there is a very weak indication in favour
of EVAR at 90 days for patients with ruptured AAA, who
are eligible for both treatments. The meta-analysis con-
tinues to suggest that women may have improved early
survival with an EVAR/endovascular strategy and that
patients in the endovascular strategy or EVAR groups
benefit from earlier hospital discharge. These data might
be sufficient for patients to prefer EVAR, but longer-term
data from all three trials will be needed to inform clinical
decision-making.
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